MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis

Zhang, Zhiyong; Zheng, Wei; Jiang, Hai

doi:10.1007/s12032-014-0984-6

Cited by 49 publications

(42 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatocellular carcinoma (HCC) is the most common primary liver cancer that is the third cause of cancer-related mortality all over the world [10]. Zhang et al [11] have demonstrated that miR148b had potential ability to suppressor tumor in HCC patients. They suggested that miR-148b has a prognostic value in clinical evaluations [11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

RETRACTED ARTICLE: Downregulation of miR-148b as biomarker for early detection of hepatocellular carcinoma and may serve as a prognostic marker

et al. 2015

View full text Add to dashboard Cite

MicroRNAs (miRNAs) have a large number of various target genes in different cancer types, which may result in many biological functions. Thus, identifying the molecular mechanisms of miRNAs may effect on the complexity of cancer progression via regulation of gene. In the current study, we utilized real-time PCR to quantify the diction of miR-148b in trail hepatocellular carcinoma (HCC) specimen and normal tissues. Furthermore, we evaluated the relationship of miR-148b and clinicopathological features with survival of HCC patients. Therefore, we evaluated the level of miR-148b expression in 101 HCC patients and also in 40 normal control cases. The result suggested lower expression in tumor tissues than normal control tissues (0.96 ± 0.14; 1.84 ± 0.20, P < 0.05). Our findings suggest that the declined expression of miR-148b can considerably be linked to tumor node metastasis (TNM) stage (stages III and IV; P = 0.021) and vein invasion (P = 0.029). Nevertheless, miR-148b expression was not related to sex (P = 0.674), age (P = 0. 523), size of tumor (P = 0.507), liver cirrhosis, and histologic grade (P = 0.734). Survival analysis showed that low expression was remarkably related to overall survival (P = 0.012). Furthermore, multivariate survival test suggested that decline of miR-148b diction was linked to poor survival in HCC patients. Our results suggested that miR-148b is decreased in HCC. Therefore, we concluded that miR-148b may play its role in the prognosis of HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Zhang et al [11] have demonstrated that miR148b had potential ability to suppressor tumor in HCC patients. They suggested that miR-148b has a prognostic value in clinical evaluations [11].…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Downregulation of miR-148b as biomarker for early detection of hepatocellular carcinoma and may serve as a prognostic marker

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In line with these findings, upregulation of miR-214 in various tumor cells increases metastasis formation (2,3,(21)(22)(23). On the other hand, miR-148b is poorly expressed in melanomas and in breast, pancreatic, and hepatocellular carcinomas (1,6,24,25) and its modulation in tumor cell lines reveals its antimetastatic function (6,(26)(27)(28). Here, by modulating miR-214 and miR-148b, respectively, in a negative and positive manner, we show that miR-214 and miR148b are part of a miR-ON-miR regulatory axis where miR-214 favors tumor dissemination following the downregulation of miR-148b and the consequent upregulation of miR-148b direct targets, ITGA5 and ALCAM as well as some of their downstream players (8).…”

Section: Discussionmentioning

confidence: 81%

miR-214 and miR-148b Targeting Inhibits Dissemination of Melanoma and Breast Cancer

et al. 2016

View full text Add to dashboard Cite

miR-214 and miR-148b have been proposed to antagonize the effects of each other in enabling or blocking metastasis, respectively. In this study, we provide evidence deepening their role and interrelationship in the process of metastatic dissemination. Depleting miR-214 or elevating miR-148b blocked the dissemination of melanoma or breast cancer cells, an effect that could be accentuated by dual alteration. Mechanistic investigations indicated that dual alteration suppressed passage of malignant cells through the blood vessel endothelium by reducing expression of the cell adhesion molecules ITGA5 and ALCAM. Notably, transendothelial migration in vitro and extravasation in vivo impaired by singly alternating miR-214 or miR-148b could be overridden by overexpression of ITGA5 or ALCAM in the same tumor cells. In clinical specimens of primary breast cancer or metastatic melanoma, we found a positive correlation between miR-214 and ITGA5 or ALCAM along with an inverse correlation of miR-214 and miR-148b in the same specimens. Our findings define an antagonistic relationship of miR-214 and miR-148b in determining the dissemination of cancer cells via tumor-endothelial cell interactions, with possible implications for microRNA-mediated therapeutic interventions aimed at blocking cancer extravasation.

show abstract

“…They could bind at the 3′ untranslated region (UTR) of a large number of target genes with imperfect complementarity, resulting in degradation of target messenger RNAs (mRNAs) and inhibition of translation [5]. miRNA dysfunction has been identified in a variety of human diseases including cancer, and a large body of evidence strongly supports the finding that miRNAs play crucial roles in cellular processes such as development, proliferation, differentiation, and apoptosis [6]. Therefore, alteration in miRNA expression is considered to have a part in cancer initiation and progression through regulating the expression of various oncogenes and tumor suppressive genes [7].…”

Section: Introductionmentioning

confidence: 99%

miR-106a* inhibits the proliferation of renal carcinoma cells by targeting IRS-2

Zhang

et al. 2015

Tumor Biol.

View full text Add to dashboard Cite

MicroRNAs play critical roles in the development and progression of human cancers. Although it has been reported that miR-106a* is downregulated in follicular lymphoma, its role in renal cell carcinoma (RCC) remains unknown. This study investigated the expression and role of miR-106a* in human RCC. Our results showed that the miR-106a* expression decreased dramatically in clinical RCC tissues and cell lines. In vitro, overexpression of miR-106a* suppressed RCC cell proliferation and S/G2 transition, whereas inhibition of miR-106a* promoted cell proliferation and S/G2 transition. It was also found that miR-106a* expression was inversely correlated with the expression of insulin receptor substrate 2 (IRS-2). IRS-2 was determined to be a direct target of miR-106a* by a luciferase reporter assay. Importantly, silencing IRS-2 resulted in the same biologic effects as those of miR-106a* overexpression in RCC cells, including inhibition of RCC cell proliferation and triggering of S/G2 cell cycle arrest with inhibition of the PI3K/Akt signaling pathway. These results indicate that miR-106a* affects RCC progression by targeting IRS-2 with suppression of the PI3K/Akt signaling pathway in RCC cells. The findings suggest miR-106a* as a novel strategy for RCC treatment.

show abstract

MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis

Cited by 49 publications

References 37 publications

RETRACTED ARTICLE: Downregulation of miR-148b as biomarker for early detection of hepatocellular carcinoma and may serve as a prognostic marker

RETRACTED ARTICLE: Downregulation of miR-148b as biomarker for early detection of hepatocellular carcinoma and may serve as a prognostic marker

miR-214 and miR-148b Targeting Inhibits Dissemination of Melanoma and Breast Cancer

miR-106a* inhibits the proliferation of renal carcinoma cells by targeting IRS-2

Contact Info

Product

Resources

About